A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model
Pre-clinical models mimicking persistent hepatitis B virus (HBV) expression are seldom, do not capture all features of a human chronic infection and due to their complexity, are subject to variability. We report a meta-analysis of seven experiments performed with TG1050, an HBV-targeted immunotherap...
Main Authors: | Roland Kratzer, Benoît Sansas, Karine Lélu, Alexei Evlachev, Doris Schmitt, Nathalie Silvestre, Geneviève Inchauspé, Perrine Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-06-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2018.1433970 |
Similar Items
-
Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01) -
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
by: Romina Salpini, et al.
Published: (2020-02-01) -
HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
by: Yael Gozlan, et al.
Published: (2022-03-01) -
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
by: Maryam Moini, et al.
Published: (2022-03-01) -
HIV/HBV Coinfection with HBsAg Seroconversion: A Case Report
by: Yasemin ÇAKIR, et al.
Published: (2024-03-01)